Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester Minnesota, USA.
CNS Neurol Disord Drug Targets. 2011 Dec;10(8):880-91. doi: 10.2174/187152711799219398.
Recent progress in enzyme engineering has led to versions of human butyrylcholinesterase (BChE) that hydrolyze cocaine efficiently in plasma, reduce concentrations reaching reward neurocircuity in the brain, and weaken behavioral responses to this drug. Along with enzyme advances, increasingly avid anti-cocaine antibodies and potent anti-cocaine vaccines have also been developed. Here we review these developments and consider the potential advantages along with the risks of delivering drug-intercepting proteins via gene transfer approaches to treat cocaine addiction.
近年来,酶工程领域的进展催生了高效水解可卡因的人丁酰胆碱酯酶(BChE)变体,从而减少可卡因进入大脑奖赏回路的浓度,并减弱对该药物的行为反应。除了酶的进步,人们还开发出了越来越高效的抗可卡因抗体和强效的抗可卡因疫苗。在此,我们对这些进展进行了综述,并探讨了通过基因转移途径来递送药物阻断蛋白以治疗可卡因成瘾的潜在优势和风险。